AnteoTech (ADO) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
11 Jun, 2026Business overview and market focus
Specializes in performance-enhancing chemicals for next-generation lithium-ion batteries and diagnostics, targeting high-growth sectors such as high silicon anodes and ceramic coated separators.
Operates two commercial businesses with combined addressable markets exceeding US $60 billion annually.
Holds 17 patents and is expanding into applications like superconductors, water treatment, coatings, and filtration.
Financial and corporate structure
Market capitalization of $88 million as of June 2026, with $12.8 million cash and no debt.
3.26 billion shares outstanding and 292 million unlisted options, with significant director and employee ownership.
Recent milestones include third-party validation of Ultranode 95 for drones and new distributor agreements in Asia.
Advanced battery technologies
Ultranode silicon anode technology offers up to 10x lithium storage by weight compared to graphite, with specific energy >390 Wh/kg at cell level.
Multiple Ultranode variants target automotive, drones, wearables, and micro-mobility markets, with commercial scale-up and validation underway.
Cross-linking additives like Anteo X and SiMRAX improve cycle life, reduce costs, and enhance safety in battery separators.
Strategic collaborations in South Korea and the US, with a focus on the rapidly growing drone battery market projected to reach $42 billion globally by 2034.
Latest events from AnteoTech
- Ultranode™ 95 validated for drones, new products launched, and cash reserves rose to A$11.2M.ADO
Q4 2026 TU - Record product evaluations and global partnerships drive growth in life sciences and batteries.ADO
Investor presentation - Cash-rich, debt-free, with major product launches and global partnerships driving growth.ADO
Q3 2026 TU - Revenue up, loss down, first commercial sales and major contract secured; going concern risk flagged.ADO
H2 2024 - Proprietary chemistry and AnteoBind NXT drive diagnostics growth and global expansion.ADO
NWR Virtual Healthcare Conference - High-silicon anode solutions deliver superior cycle life, scalability, and cost efficiency.ADO
Investor presentation - Net loss narrowed 36% to $1.4M, with $3.5M raised to support growth and global expansion.ADO
H1 2026 - Technical and commercial progress in batteries and diagnostics, with strengthened funding for 2026.ADO
Q2 2026 TU - $5.0M cash, strategic review, and strong AnteoBind demand amid slow battery market.ADO
Q3 2025 TU